LYKALABS.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 12:59):

Stats
Šios dienos apimtis	75 916.00
Vidutinė apimtis	120 109
Rinkos kapitalizacija	4.08B
EPS	INR0 ( 2024-02-08 )
Kita pelno data	( INR0 ) 2024-05-20
Last Dividend	INR2.50 ( 1996-08-12 )
Next Dividend	INR0 ( N/A )
P/E	-100.12
ATR14	INR0.321 (0.26%)

Tūris Koreliacija

Ilgas: -0.28 (neutral)

Trumpas: 0.74 (moderate)

Signal:(46.434) Neutral

Lyka Labs Limited Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Lyka Labs Limited Koreliacija - Valiuta/Žaliavos

-0.37
( neutral )

-0.67
( moderate negative )

-0.23
( neutral )

0.40
( neutral )

-0.22
( neutral )

0.50
( neutral )

Lyka Labs Limited Finansinės ataskaitos

Annual	2022
Pajamos:	INR930.73M
Bruto pelnas:	INR555.18M (59.65 %)
EPS:	INR-4.57

FY	2022
Pajamos:	INR930.73M
Bruto pelnas:	INR555.18M (59.65 %)
EPS:	INR-4.57

FY	2022
Pajamos:	INR1.84B
Bruto pelnas:	INR1.30B (70.97 %)
EPS:	INR13.57

FY	2021
Pajamos:	INR671.07M
Bruto pelnas:	INR291.40M (43.42 %)
EPS:	INR-4.07

Financial Reports:

No articles found.

Lyka Labs Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Lyka Labs Limited Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 2.22 - No dividend growth expected in the near future

Information

First Dividend	INR2.50	1995-09-11
Last Dividend	INR2.50	1996-08-12
Next Dividend	INR0	N/A
Payout Date	1996-10-01
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	INR5.00	--
Avg. Dividend % Per Year	0.00%	--
Score	0.84	--
Div. Sustainability Score	0
Div.Growth Potential Score	2.22
Div. Directional Score	1.072	--

Next Divdend (Est)
(2024-07-22)

INR0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.84

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
1995	INR0	0.00%
1996	INR0	0.00%
1997	INR0	0.00%
1998	INR0	0.00%
1999	INR0	0.00%
2000	INR0	0.00%
2001	INR0	0.00%
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0	0.00%
2019	INR0	0.00%
2020	INR0	0.00%
2021	INR0	0.00%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
RITES.NS	Dividend Knight	2023-09-08	Quarterly	7	3.95%
LAMBODHARA.NS	Dividend Junior	2023-09-14	Annually	10	0.87%
FORCEMOT.NS	Dividend Junior	2023-09-21	Annually	6	0.45%
APLAPOLLO.NS	Ex Dividend Junior	2023-09-01	Sporadic	13	0.07%
TATVA.NS	Dividend Junior	2023-09-08	Annually	3	0.04%
NUCLEUS.NS	Dividend Junior	2023-07-07	Annually	22	1.41%
INDUSINDBK.NS	Dividend Junior	2023-06-02	Annually	23	0.56%
COLPAL.NS	Dividend Knight	2023-05-19	Semi-Annually	18	1.38%
SBIN.NS	Dividend Junior	2023-05-31	Sporadic	29	0.99%
MAHSEAMLES.NS	Dividend Junior	2023-08-14	Annually	21	0.80%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0336	1.500	-0.672	-1.007	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	-0.125	1.500	-2.50	-3.75	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	0.735	1.000	-0.839	-0.839	[3 - 30]
operatingCashFlowPerShareTTM	8.01	2.00	7.33	10.00	[0 - 30]
freeCashFlowPerShareTTM	8.01	2.00	6.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.614	1.000	3.11	3.11	[0.2 - 0.8]
operatingProfitMarginTTM	0.0464	1.000	-1.072	-1.072	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				-0.0770

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-114.85	1.000	-10.00	0	[1 - 100]
returnOnEquityTTM	-0.125	2.50	-1.606	-3.75	[0.1 - 1.5]
freeCashFlowPerShareTTM	8.01	2.00	7.33	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	8.01	2.00	7.33	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.860	1.500	7.60	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.251	1.000	6.23	0	[0.1 - 0.5]
Total Score				2.22

Lyka Labs Limited

Lyka Labs Limited, a pharmaceutical company, engages in development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, muscle relaxant, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers contracted manufacturing services to various large pharmaceutical companies; and medical and technical assistance in the areas of manufacturing know how and manufacturing facilities, as well as technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. In addition, it provides products and services in therapeutic categories, such as intensive care, gastroenterology, anti-infective, anti-fungal, surgery care, cosmetologist, urology, wound care, and anesthesia, as well as deals in pharmaceutical products. The company offers its products in various formulations, including injections, creams, ointments, gels, and lotions. It also exports its products to Bangladesh, Combodia, Congo, Costa Rica, Peru, Romania, Russia, Sri Lanka, Sudan, Ukraine, Venezuela, and Vietnam. Lyka Labs Limited was incorporated in 1976 and is based in Mumbai, India.